Radiprodil
As of the edition of 20 October 2026, Radiprodil is a small molecule: in active development; acts on GRIN1 and GRIN2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 8, 2 stopped early
- Disease areas
- Nervous system; Cancer; Inherited and neonatal; Hormones; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B and 2 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Radiprodil.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Radiprodil.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 2 | 1 |
| Phase 2 | 3 | 1 | 1 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Actavis | Lead sponsor of trials | 2009 to now |
| UCB | Lead sponsor of trials | 2016 to now |
| GRIN Therapeutics | Lead sponsor of trials | 2023 to now |